Operating Lease, Right-of-Use Asset of Acrivon Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Acrivon Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Acrivon Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $2,792,000, a 26% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Acrivon Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,792,000 -$1,005,000 -26% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,052,000 -$924,000 -23% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $3,306,000 -$899,000 -21% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $3,554,000 -$875,000 -20% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $3,797,000 -$389,000 -9.3% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $3,976,000 -$408,000 -9.3% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $4,205,000 -$374,000 -8.2% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $4,429,000 -$341,000 -7.1% 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $4,186,000 -$772,000 -16% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $4,384,000 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 $4,579,000 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $4,770,000 -$731,000 -13% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $4,958,000 30 Sep 2022 10-Q 15 Dec 2022 2022 Q3
Q4 2021 $5,501,000 31 Dec 2021 10-K 28 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.